
Home » Ações » Ações da NASDAQ / Bolsa de Valores da NASDAQ » Buy Alnylam Pharmaceuticals Stocks
Are you looking to buy Alnylam Pharmaceuticals stocks? Chech our Reportlab with an in-depth review, check prices, statistics and see if buying this stock is interesting right now. This article will help you buy NASDAQ:ALNY! and analyze the company to see if this stock might be an interesting option to invest in. We will enlighten you about Alnylam Pharmaceuticals stocks and how to buy and use them. Click on the button to start reading the review right now or scroll down for real time statistics about this company.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company’s pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP). In addition, the company is developing givosiran for the treatment of patients with AHP; lumasiran for the treatment of primary hyperoxaluria type 1, or PH1; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc., as well as collaboration with Vir Biotechnology, Inc. to advance RNAi therapeutics for the treatment of coronavirus infection, including COVID-19. It also has a collaboration and license agreement with Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational ribonucleic acid interference therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease, as well as Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Volume médio
942,133 shs
MERCADO CAP
$19.17 billion
Bolsa de Valores
NASDAQ
Comprem essas ações!
NOME
|
TICKER
|
INDÚSTRIA
|
SECTOR
|
VOLUME
|
COMPRAR AGORA ESSAS AÇÕES
|
---|---|---|---|---|---|
NASDAQ:ALNY
|
Preparações farmacêuticas
|
Médico
|
15,685 shs
|
Below is a quick guide on how to buy NASDAQ:ALNY stocks safe, fast and around the world in less than five minutes.
Passo 1: Abrir uma conta no eToro – eToro is the best broker to buy Alnylam Pharmaceuticals shares in the world as you won’t pay any commissions. To do this, visit the eToro website and open an account, it is 100% safe and they offer a huge amount of stocks.
Passo 2: Carregue sua identificação - Conforme os regulamentos da KYC, eToro lhe pedirá que carregue uma cópia de seu passaporte ou de sua carteira de motorista.
Etapa 3: Fundos de depósito - Deposite algum dinheiro em sua recém-criada conta eToro. O senhor pode escolher entre transferência bancária, carteira eletrônica, cartão de débito/crédito ou Paypal.
Passo 4: Buy Alnylam Pharmaceuticals – Search for “”NASDAQ:ALNY”” and click on the “”Trade”” button. Enter the total amount of your investment (minimum $50) and confirm the order by clicking the “”Open Trade”” button. And that’s it: you have just bought Alnylam Pharmaceuticals stocks with 0% commission!.
1 | ![]() | Depósito mínimo $50 Promoção exclusiva | Nossa pontuação 10 ★★★★★ | 0% comissão |
18 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” Alnylam Pharmaceuticals stock.
Wall Street analysts have given Alnylam Pharmaceuticals a “Buy” rating, but there may be better short-term opportunities in the market. Some of Reportlab’s past winning trading ideas have resulted in 5-15% weekly gains. Reportlab just released five new trading ideas, but Alnylam Pharmaceuticals wasn’t one of them. Reportlab thinks five stocks may be even better buys in the how to buy stocks guide.
1 | ![]() | Depósito mínimo $50 Promoção exclusiva | Nossa pontuação 10 ★★★★★ | 0% comissão |
2 | ![]() | Depósito mínimo $50 Promoção exclusiva | Nossa pontuação 10 ★★★★★ | 0% comissão |
3 | ![]() | Depósito mínimo $50 Promoção exclusiva | Nossa pontuação 10 ★★★★★ | 0% comissão |
It can be difficult to navigate through all the outdated and incorrect information related to purchasing NASDAQ:ALNY stocks. We believe that stocks should be accessible for all, which is why we’ve created this handy guide on where to buy Alnylam Pharmaceuticals stocks with a step by step approach.
You’ll need to register with a broker, in these times you can’t go without once and it’s crucial to use a regulated broker that’s allowed to operate there, otherwise, you risk losing funds. eToro is one such broker, and one of the best brokers to buy Alnylam Pharmaceuticals stocks with 0% comission, to sign up just click on open account in the following table or compare other options.
Como o eToro é uma plataforma regulamentada, o senhor precisará completar o processo KYC, isso é uma prática padrão e leva apenas alguns minutos. O senhor precisará fornecer um documento de identificação com foto (passaporte, carteira de motorista) e comprovante de endereço (conta de serviços públicos, extrato bancário).
Uma vez que o senhor tenha se inscrito e verificado sua conta, precisará depositar fundos. eToro aceita cartões de crédito/débito, transferências bancárias, e também carteiras eletrônicas. Portanto, qualquer que seja sua preferência, haverá algo para o senhor.
Now that you’ve funded your eToro account, just type “NASDAQ:ALNY stocks” na barra de busca na parte superior da tela e pressione "trade".
All that’s left is to buy some NASDAQ:ALNY stock. Simply enter the amount you want to purchase and hit the “buy” button. The amount you bought will be automatically credited to your account where you can monitor its performance.
All in all, NASDAQ:ALNY is an incredibly interesting company that has the potential to solve some major issues in the business space. After reading this guide you should know how to buy this investment using the best broker or platform. We recommend eToro to anyone looking for a regulated, easy-to-use, fully-featured broker to buy Alnylam Pharmaceuticals stocks. As with any broker or online platform, it’s crucial you set up 2FA when using their tools as it ensures your funds are completely safe.
Alnylam Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals will be holding an earnings conference call on Thursday, February 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its quarterly earnings results on Tuesday, November, 10th. The biopharmaceutical company reported ($2.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.66) by $0.52. The biopharmaceutical company had revenue of $125.85 million for the quarter, compared to the consensus estimate of $119.05 million. Alnylam Pharmaceuticals had a negative net margin of 222.19% and a negative trailing twelve-month return on equity of 65.96%. Alnylam Pharmaceuticals’s revenue was up 79.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.50) EPS.
View Alnylam Pharmaceuticals’ earnings history.
Alnylam Pharmaceuticals’ stock was trading at $101.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALNY shares have increased by 62.1% and is now trading at $165.21.
Launched in 2006, eToro is, in our opinion, without a doubt the best broker for buying NASDAQ:ALNY stocks in the world. The onboarding process is simple, it’s designed to make sure even those new to the stock market are ready to start investing the shortest amount of time possible. As a regulated platform you gain several benefits, most importantly, you know they’re not going to run off with your hard-earned money./
Mais de 95% de fundos de clientes são mantidos offline, em câmara fria, o que é crucial para qualquer corretor que administre seus ativos. Independentemente de quão segura deve ser uma plataforma, recomendamos o uso do 2FA para acrescentar uma camada adicional de segurança à sua conta.
eToro oferece aos usuários uma gama de recursos para começar a investir o mais rapidamente possível. Eles têm uma característica relativamente única chamada negociação de cópias, que lhe permite ganhar uma renda passiva ao espelhar comerciantes experientes, o que lhe permite começar a ter lucro rapidamente, e lhe dá uma melhor compreensão das estratégias usadas pelos profissionais. Além disso, o eToro permite aos usuários investir em carteiras administradas, sendo uma carteira administrada uma variedade de ativos semelhantes agrupados, permitindo ao senhor diversificar sua conta, reduzindo qualquer risco potencial. Para aqueles com experiência anterior em negociação, o senhor pode investir em mercados fora das ações, já que eToro permite aos usuários negociar ETFs, commodities, criptografia e índices. Se o senhor já investir fora do espaço da bolsa de valores, isso pode ser muito útil, pois permite ao senhor administrar todos os seus investimentos em um só lugar.
18 Wall Street analysts have issued 12-month price targets for Alnylam Pharmaceuticals’ stock. Their forecasts range from $74.00 to $225.00. On average, they expect Alnylam Pharmaceuticals’ stock price to reach $159.17 in the next twelve months. This suggests that the stock has a possible downside of 3.7%.
View analysts’ price targets for Alnylam Pharmaceuticals or view top-rated stocks among Wall Street analysts.
Alnylam Pharmaceuticals’ management team includes the following people:
Dr. John M. Maraganore, CEO & Exec. Director (Age 58, Pay $1.79M)
Dr. Yvonne L. Greenstreet M.B.A., MBChB, MBA, Pres & COO (Age 58, Pay $1.14M)
Mr. Jeffrey V. Poulton, Chief Financial Officer (Age 53, Pay $681.75k)
Dr. Akshay K. Vaishnaw, Pres of R&D (Age 58, Pay $986.1k)
Dr. Alfred W. Boyle Ph.D., Sr. VP of Technical Operations
Dr. Kevin Fitzgerald, Sr. VP & Chief Scientific Officer
Ms. Christine Regan Lindenboom, Sr. VP of Investor Relations & Corp. Communications
Ms. Laurie Bartlett Keating J.D., Exec. VP, Chief Legal Officer & Sec. (Age 67)
Ms. Agnieszka Gallagher, Chief Ethics & Compliance Officer
Mr. Mark Baglin, VP of Global Marketing
Os CFDs são instrumentos complexos e vêm com um alto risco de perder dinheiro rapidamente devido à alavancagem. 68% de contas de investidores de varejo perdem dinheiro ao negociar CFDs com esse provedor. O senhor deve considerar se compreende como os CFDs funcionam, e se pode arcar com o alto risco de perder seu dinheiro.
65 employees have rated Alnylam Pharmaceuticals CEO John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among Alnylam Pharmaceuticals’ employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
Some companies that are related to Alnylam Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Exact Sciences (EXAS), Incyte (INCY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and United Therapeutics (UTHR).
View all of ALNY’s competitors.
Based on aggregate information from Reportlab watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).
Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol “ALNY.”
1 | ![]() | Depósito mínimo $50 Promoção exclusiva | Nossa pontuação 10 ★★★★★ | 0% comissão |
Alnylam Pharmaceuticals’ stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.51%), First Trust Advisors LP (0.48%), Swiss National Bank (0.38%), Sumitomo Mitsui Trust Holdings Inc. (0.33%), California Public Employees Retirement System (0.29%) and State of Wisconsin Investment Board (0.16%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Philip A Sharp, Phillip A Sharp, Steven M Paul and Yvonne Greenstreet.
View institutional ownership trends for Alnylam Pharmaceuticals.
ALNY stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., First Trust Advisors LP, Sumitomo Mitsui Trust Holdings Inc., Kornitzer Capital Management Inc. KS, Robeco Institutional Asset Management B.V., Assenagon Asset Management S.A., Swiss National Bank, and Strs Ohio. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Phillip A Sharp, Steven M Paul, and Yvonne Greenstreet.
View insider buying and selling activity for Alnylam Pharmaceuticals or view top insider-selling stocks.
ALNY stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Rhenman & Partners Asset Management AB, Victory Capital Management Inc., Exchange Traded Concepts LLC, NN Investment Partners Holdings N.V., Spectrum Planning & Advisory Services Inc., SkyOak Wealth LLC, and Nisa Investment Advisors LLC.
View insider buying and selling activity for Alnylam Pharmaceuticals or or view top insider-buying stocks.
Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the stock market include Revisão dos Corretores Interativos, Revisão eToro, Revisão DEGiro, Revisão da AvaTrade, IG Markets Review, Revisão dos Mercados de IC, CMC Markets Review, Admiral Markets Review e muitos mais. Leia uma das revisões para saber tudo sobre o corretor e comece agora a comprar ações.
One share of ALNY stock can currently be purchased for approximately $165.21.
Alnylam Pharmaceuticals has a market capitalization of $19.19 billion and generates $219.75 million in revenue each year. The biopharmaceutical company earns $-886,120,000.00 in net income (profit) each year or ($8.11) on an earnings per share basis.
No Reportlab.org queremos garantir que o senhor tenha todas as informações mais relevantes sobre compra de ações. Trazemos-lhe os melhores guias sobre o mercado de ações, com revisões pessoais, informações de base, revisões de plataforma, como fazer e muito mais. Deseja obter outras informações? Então confira os Ações OTC, Ações da NASDAQ, Ações da NYSE, Ações LONES, Ações de FRA, Ações ETR, Ações da APE, Ações TSX ou Ações Amex. Procurando informações mais detalhadas como Ações de 5g, ações biotecnológicas, estoques de ouro e outras informações de nosso reportlab.
How can you buy Alnylam Pharmaceuticals stock on the internet?
You can easily buy Alnylam Pharmaceuticals stocks with one of the well known regulated brokers on the internet. You can open an account within 5 minutes, make deposits with countless payment providers and trade with professional tools on their platform. At the moment, our visitors rate eToro as the most popular choice.
Outra opção é usar um corretor regulamentado como Mercados de IC ou Corretores Interativos. You can an account with these brokers and start buying or trading NASDAQ:ALNY stocks in a safe and complete environment to trade in.
Where to buy Alnylam Pharmaceuticals stock?
You will first want to find a licensed broker that supports NASDAQ:ALNY stock. One of our favourite brokers, eToro for example, allows you to make investments into this asset from just $25 and only charges you the spread. Another option is using a regulated broker like DEGIRO or Interactive Brokers. You can open an account with these brokers and start buying or trading NASDAQ:ALNY stocks in a safe and complete environment.
Is NASDAQ:ALNY stock a good investment?
As with any other asset, there is an element of risk associated with buying NASDAQ:ALNY stocks. Therefore, you will want to study the market and make a decision based on your financial standing and the risk you are willing to take.
Is Alnylam Pharmaceuticals stock safe to invest in?
All stocks are volatile, or affected by market circumstances. The case with NASDAQ:ALNY is no different, with its price fluctuating dramatically within short periods. As such, if the market goes against you, then you will end up facing a loss. We advice you to do research first before investing in Alnylam Pharmaceuticals stock.
How do you trade Alnylam Pharmaceuticals stocks?
You can trade stocks by first opening an account with a regulated platform and making a deposit in US dollars, EUROs or other currency. Next, search for Alnylam Pharmaceuticals stock and choose from a buy or sell order – depending on whether you think the stock asset will rise or fall in value. If you speculated on NASDAQ:ALNY stocks correctly, you will have made a profit. The size of your trading profit will ultimately be determined by your stake and at what percentage your position grew.
How to sell Alnylam Pharmaceuticals stock?
To sell your NASDAQ:ALNY stocks investment, you can sign in to your broker account and cash out directly from within your portfolio. If you have stored the stocks elsewhere, you will first have to transfer them to a third-party provider or broker to cash out.
What is the best Alnylam Pharmaceuticals stock trading platform?
eToro, is a top-rated platform for beginners, albeit, it charges significantly lower fees. For example, there are no fees to deposit with a debit/credit card and you only need to cover the spread when trading NASDAQ:ALNY stock.
Stephen sabe muito sobre produtos financeiros e, em particular, tem uma grande paixão pelas bolsas de valores e por seus participantes. Esperamos que a informação fornecida ajude o senhor. Algo não está muito claro? Queira deixar suas perguntas ou comentários no final da página.
![]() | Nossa pontuação ★★★★★ | |
![]() | Nossa pontuação ★★★★★ | |
![]() | Nossa pontuação ★★★★★ |
Boletim informativo
![]() |
Nossa pontuação |
0% comissão |
Bolsa de Valores de Paris (EPA)
Todas as ações da EPA Mais informações Ações da EPA O que é a Bolsa de Valores de Paris (EPA)? Agora
Ações em tempo real e dados criptográficos
Notificações, Dicas e Notícias
Melhores Ações e Guias Criptográficos
Corretor Online & Câmbio de Revisões
Reportlab Finanças é puramente um website informativo e em nenhum caso implica aconselhamento sobre investimentos. Todos os investimentos comportam riscos e o senhor pode perder todos os seus investimentos. Não invista dinheiro que o senhor não pode perder.
Reportlab Finanças
38 Holburn Lane
Heckfield Green
IP21 0UB
Reino Unido
Copyright © 2022 Reportlab.Finance | Todos os direitos reservados.